Annovis Bio, Inc. (ANVS)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 5,161,921 | |||
| General and administrative | 1,109,532 | |||
| Total operating expenses | 6,271,453 | |||
| Operating loss | -6,271,453 | |||
| Interest income | 191,395 | |||
| Change in fair value of warrants | -140,000 | |||
| Total other income, net | 51,395 | |||
| Net loss | -6,220,058 | |||
| Earnings per share, basic | -0.32 | |||
| Earnings per share, diluted | -0.32 | |||
| Weighted average number of shares outstanding, basic | 19,486,231 | |||
| Weighted average number of shares outstanding, diluted | 19,486,231 | |||